A randomized treatment trial: Single versus 7-day dose of metronidazole for the treatment of trichomonas vaginalis among HIV-infected women

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 5, 2010, Pages 565-571

  Kissinger, Patricia ^a   Mena, Leandro ^b   Levison, Judy ^c   Clark, Rebecca A ^d   Gatski, Megan ^a   Henderson, Harold ^b   Schmidt, Norine ^a   Rosenthal, Susan L ^e   Myers, Leann ^a   Martin, David H ^d  

^a TULANE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

HIV infected women; metronidazole; patient delivered partner treatment; Trichomonas vaginalis

Indexed keywords

METRONIDAZOLE;

ADULT; AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG INDUCED HEADACHE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEXUALITY; SINGLE DRUG DOSE; TASTE DISORDER; TREATMENT DURATION; TRICHOMONIASIS; VIRUS LOAD; VOMITING;

ADULT; ANTITRICHOMONAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; METRONIDAZOLE; MIDDLE AGED; SEXUAL PARTNERS; TRICHOMONAS INFECTIONS; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS;

EID: 78650197385     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181eda955     Document Type: Article

References (43)

1. Gerbase AC, Rowley JT, Heymann DH, et al. Global Prevalence and Incidence Estimates of Selected Curable STDs. Sex Transm Infec. 1998; 74 (Suppl 1):S12-S16.
2. Swygard H, Sena AC, Hobbs MM, et al. Trichomoniasis: clinical manifestations, diagnosis and management. Sex Transm Infect. 2004;80: 91-95.
3. Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet. 1998;351:213-214.
4. Sorvillo F, Smith L, Kerndt P, et al. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis. 2001;7:927-932.
5. Tuomala RE, O'Driscoll PT, Bremer JW, et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis. 2003;187:375-384.
6. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis. 2001;183:206-212.
7. Pearce-Pratt R, Phillips DM. Studies of adhesion of lymphocytic cells: implications for sexual transmission of human immunodeficiency virus. Biol Reprod. 1993;48:431-445.
8. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis. 2001;183:1017-1022.
9. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36:11-16.
10. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis. 2003;30:839-843.
11. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis. 2000;27:284-288.
12. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis. 2008;46:994-999.
13. Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis. 2006;33:445-450.
14. Van Der Pol B, Williams JA, Orr DP, et al. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis. 2005;192:2039-2044.
15. Das S, Huengsberg M, Shahmanesh M. Treatment failure of vaginal trichomoniasis in clinical practice. Int J STD AIDS. 2005;16:284-286.
16. CDC. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006 55 52-54.
17. Tidwell BH, Lushbaugh WB, Laughlin MD, et al. A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis. J Infect Dis. 1994;170:242-246.
18. Spence MR, Harwell TS, Davies MC, et al. The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study. Obstet Gynecol. 1997;89(5 Pt 1):699-703.
19. Antonelli NM, Diehl SJ, Wright JW. A randomized trial of intravaginal nonoxynol 9 versus oral metronidazole in the treatment of vaginal trichomoniasis. Am J Obstet Gynecol. 2000;182:1008-1010.
20. Woodcock KR. Treatment of trichomonal vaginitis with a single oral dose of metronidazole. Br J Vener Dis. 1972;48:65-68.
21. Thin RN, Symonds MA, Booker R, et al. Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis. Br J Vener Dis. 1979;55:354-356.
22. Hager WD, Brown ST, Kraus SJ, et al. Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens. JAMA. 1980;244: 1219-1220.
23. duBouchet L, Spence MR, Rein MF, et al. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis. 1997;24:156-160.
24. Fleury FJ, Van Bergen WS, Prentice RL, et al. Single dose of two grams of metronidazole for Trichomonas vaginalis infection. Am J Obstet Gynecol. 1977;128:320-323.
25. Schwebke JR, Morgan SC, Pinson GB. Validity of self-obtained vaginal specimens for diagnosis of trichomoniasis. J Clin Microbiol. 1997;35: 1618-1619.
26. Gatski M, Mena L, Levison J, et al. Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among HIV-infected women. Sex Transm Dis. May 24, 2010. [Epub ahead of print].
27. Caliendo AM, Jordan JA, Green AM, et al. Real-time PCR improves detection of Trichomonas vaginalis infection compared with culture using self-collected vaginal swabs. Infect Dis Obstet Gynecol. 2005;13:145-150.
28. Madico G, Quinn TC, Rompalo A, et al. Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples. J Clin Microbiol. 1998;36:3205-3210.
29. Wendel KA, Erbelding EJ, Gaydos CA, et al. Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoni-asis. Clin Infect Dis. 2002;35:576-580.
30. Peterman TA, Tian LH, Metcalf CA, et al. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis. 2009;48:259-260.
31. Piantadosi S Clinical Trials: A Methodologic Perspective. 2nd ed. Hoboken, NJ: Wiley-Interscience; 2005.
32. Dunne RL, Dunn LA, Upcroft P, et al. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res. 2003;13: 239-249.
33. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50:4209-4210.
34. Perez S, Fernandez-Verdugo A, Perez F, et al. Prevalence of 5-nitroimidazole-resistant trichomonas vaginalis in Oviedo, Spain. Sex Transm Dis. 2001;28:115-116.
35. Schmid G, Narcisi E, Mosure D, et al. Prevalence of metronidazole- resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46:545-549.
36. Sorvillo F, Kovacs A, Kerndt P, et al. Risk factors for trichomoniasis among women with human immunodeficiency virus (HIV) infection at a public clinic in Los Angeles County, California: implications for HIV prevention. Am J Trop Med Hyg. 1998;58:495-500.
37. Kissinger PJ, Dumestre J, Clark RA, et al. Vaginal swabs versus lavage for detection of Trichomonas vaginalis and bacterial vaginosis among HIV-positive women. Sex Transm Dis. 2005;32:227-230.
38. Seth P, Wingood GM, Diclemente RJ. Exposure to alcohol problems and its association with sexual behaviour and biologically confirmed Trichomonas vaginalis among women living with HIV. Sex Transm Infect. 2008;84:390-392.
39. Clark RA, Theall KP, Amedee AM, et al. Frequent douching and clinical outcomes among HIV-infected women. Sex Transm Dis. 2007;34: 985-990.
40. Gatski M, Kissinger P. Observation of probable persistent, undetected Trichomonas vaginalis infections among HIV-positive women. Clin Infect Dis. 2010;51:114-115.
41. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. HIV/AIDS surveillance report 2007. In Services USDoHaH. ed. Vol 19. 2009.
42. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis. 2007;45:1319-1326.
43. Helms DJ, Mosure DJ, Metcalf CA, et al. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex Transm Dis. 2008;35:484-488.